Several studies have proved the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors, and thus both Dapagliflozin and Empagliflozin are strongly recommended for heart failure treatment [66,67]. Here, SLC5A2 is linked to heart failure.